Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology; D002460:Cell Line; D003520:Cyclophosphamide / Q000008:administration & dosage*; D003602:Cytotoxicity, Immunologic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006084:Graft Rejection; D007274:Injections, Intraperitoneal; D008264:Macrophages / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D010954:Plasmacytoma / Q000188:drug therapy* / Q000276:immunology; D013154:Spleen / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
D000912:Antibodies, Neoplasm; D003520:Cyclophosphamide